Véronique Dieras is an expert in Oncology at Centre Eugène Marquis (France). As of June 2026, ScienceLeadR ranks Véronique Dieras in the top 1% of experts worldwide for Breast Diseases and Breast Neoplasms. Véronique Dieras has authored 589 publications, the most recent in 2025, and is an investigator in 49 clinical trials, 1 of them ongoing. SLR score: 2,120 (community average: 125). How the SLR is computed.

LeadR Profile

Véronique Dieras Centre Eugène Marquis France
2 120 ScienceLeadR Reputation 2120
Network Map

Oncology

Subspecialties: Biochemistry - Dermatology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1995 - 2025

Source: PubMed

Centre Eugène Marquis

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 589

Citations

Citations: 40 353 1st author: 57 Last author: 52 Unique author: 7


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer.
PMID 41369677 — safety, breast neoplasms, neoplasms, transaminases, maintenance, hormones, breast, therapeutics, medical oncology, trastuzumab
J Clin Oncol Top journal20250
Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectives.
PMID 40849221 — breast neoplasms, brain, neoplasms, breast, physicians, breast diseases
Breast20251
Comparative performance of a targeted next-generation sequencing assay against multiplexed digital PCR assays in detecting ERBB2, ESR1, and PIK3CA mutations in plasma circulating cell-free DNA from liquid biopsies.
PMID 41072730 — cells, genes, high-throughput nucleotide sequencing, breast neoplasms, polymerase chain reaction, neoplasms, multiple chronic conditions, biopsy, cell-free nucleic acids, solutions, breast, dna, liquid biopsy, mutation, plasma
J Mol Diagn20250
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort.
PMID 40967066 — breast neoplasms, neoplasms, disease progression, drug therapy, breast, therapeutics, chemotherapy
ESMO Open20250
[Hormone therapy in the adjuvant setting based on risk assessment].
PMID 40617721 — risk assessment, neoplasms, hormones, therapeutics
Bull Cancer20250

Clinical Studies 49

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3 Study Chair: 3

By phase:

Phase 3 20
Phase 2 13
Phase 1 8
Phase 1/Phase 2 5
N/A 3

By status:

Completed 36
Terminated 6
Unknown 3
Active not recruiting 2
Recruiting 2

By type:

Interventional 47
Observational 2

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 4
multicentric5to9 8
multicentricup10 33

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2 Breast Cancer
NCT05132582 — injections, skin, breast neoplasms, genetics, pharmaceutical preparations, neoplasms, maintenance, breast, therapeutics, mouth, injections, subcutaneous, veins, trastuzumab, hyaluronoglucosaminidase
Phase 3Active not recruiting2022

LeadR Networks

Main global connection map